Head to Head Review: Eloxx Pharmaceuticals (NASDAQ:ELOX) and LadRx (OTCMKTS:CYTR)

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of LadRx shares are owned by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 12.8% of LadRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Eloxx Pharmaceuticals has a beta of -1629.93, suggesting that its stock price is 163,093% less volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.

Valuation and Earnings

This table compares Eloxx Pharmaceuticals and LadRx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$36.06 million	($9.07)	N/A
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A

Profitability

This table compares Eloxx Pharmaceuticals and LadRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
LadRx	N/A	-67.61%	-45.39%

Summary

Eloxx Pharmaceuticals beats LadRx on 5 of the 8 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.